Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

News

Promising results from the  preclinical study conducted by Menarini Ricerche on  MEN1611 , a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development  for the treatment ...
The Board of Directors has appointed Mrs.  Elcin Barker Ergun   as CEO of Menarini Group.
Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205 Antibody-Drug Conjugate (ADC)  MEN1309 /OBT076. These findings have been published by...
All News »
12 Sep 2019

Menarini: Elcin Barker Ergun Group CEO

Florence, 12th September 2019 - The Board of Directors has appointed Mrs. Elcin Barker Ergun  as CEO of Menarini Group.

Elcin Barker Ergun  is the ideal addition to the Menarini team, in order to  continue the agenda of growth  in geography and therapeutic areas - commented Eric Cornut, Chairman of Menarini.



Elcin Barker Ergun:  Menarini is a company admired on a global level for both its market dynamism and patient centricity. It is an honour for me to join Menarini and contribute in capturing new business opportunities and further drive our globalization.

The arrival of Elcin Barker Ergun  – commented Lucia and Alberto Giovanni Aleotti – completes the process we started a few years ago with the aim of strengthening the governance  and making the company more international in order to accelerate its growth.

After 8 years working in technology sector in the UK and the Netherlands, Elcin Barker Ergun  entered the pharmaceutical industry with Smithkline Beecham as subsidiary CFO. She then joined Merck KGaA’s Healthcare business where she covered positions of increasing seniority with global business responsibilities as well as managing R&D collaborations in her last role heading New Business.

 

Elcin Barker Ergun has worked in Global, Regional and Local leadership roles in Pharma Industry for more than 20 years including Commercial, Finance and Innovation leadership.
In her last role she was Head of New Business of Merck KGaA’s Healthcare division based in Boston in charge of an entity carrying out external development and financing of several assets to create new businesses. Prior to that, she was Executive Vice President, Head of Global Commercial for Merck Serono  responsible for a P&L of €4.5 billion and over 5,000 people. Prior to that, she was Senior Vice President, Head of Intercontinental Region comprising of 69 countries across Middle East, Africa, Turkey, Russia/CIS.

In her earlier career, Elcin held several finance roles as subsidiary CFO Smithkline Beecham and as subsidiary CFO for Honeywell. She also spent 8 years working in technology sector in the UK and the Netherlands, before entering pharma industry. Elcin is an engineer with an MBA from INSEAD.


Diagnostics

Advanced technology.

READ MORE »

Menarini in the world.

The Menarini Group has companies located almost all over the world.

READ MORE »

Our values

 

10 core values have influenced the progress of our group.

READ MORE »

Open positions

We are looking for talented people. Discover the opportunities!!

READ MORE »